Remus Pharmaceuticals Limited, established in 2015, specializes in the commercialization and dissemination of finalized compositions of pharmaceutical medications.
The company’s assortment of products can be categorized into two principal divisions:
- Active Pharmaceutical Ingredients (APIs): These are the biologically potent constituents found in drug formulations such as tablets, capsules, creams, and injectables, which generate the desired effects.
- Refined Pharmaceutical Formulations: Therapeutic medications are offered in various forms and dosages.
As of January 31, 2023, the company boasts an extensive portfolio comprising 429 different products. These offerings are marketed under diverse brand appellations worldwide. At the date mentioned above, the company had registered 295 products across 13 countries. Furthermore, 134 products were undergoing the registration process in 16 countries.
Moreover, by January 31, 2023, Remus Pharmaceuticals had secured business-to-business supply agreements with 58 domestic distributors and 139 international distributors for the purposes of distribution and/or contract manufacturing supply.
Notably, the company has diligently fostered steadfast and reliable relationships with a diverse clientele spanning over 20 countries. This client base encompasses generic distributors, regional distributors, multinational distributors, as well as hospitals and clinics.
Remus Pharmaceuticals is One of the largest manufacturers and exporters of formulations in India. Remus succeeds in utilizing the best of its resources and manpower to develop its network throughout the world. The company is backed by specialists with 15 years of industry expertise and was built on ties with leading pharmaceutical firms.
Companies Specialties:
- Oncology: This specialty focuses on the diagnosis, treatment, and management of various types of cancer.
- Probiotics: Probiotics are live microorganisms that provide health benefits when consumed. They are commonly used to promote digestive health and boost the immune system.
- Ophthalmic: This specialty relates to the eyes and involves the diagnosis and treatment of eye conditions and diseases.
- Contrast Reagents: Contrast reagents, also known as contrast agents or contrast media, are substances used in medical imaging procedures to enhance the visibility of specific organs, tissues, or blood vessels.
- Sachets: Sachets are small, sealed packets used for packaging and dispensing various forms of medications or products, such as powders, granules, or liquids.
- Inhalers: Inhalers are devices used to deliver medication directly into the lungs for the treatment of respiratory conditions, such as asthma or chronic obstructive pulmonary disease (COPD).
- Semi-solids: Semi-solid pharmaceutical preparations refer to formulations that have a partially solid consistency, such as creams, ointments, gels, or pastes.
- Large-Volume Parenterals: Large-volume parenteral (LVPs) are sterile solutions or suspensions intended for intravenous administration in large volumes, typically over 100 milliliters. They are commonly used for hydration, nutritional support, or administration of medications.
- Injections: Injections involve the delivery of medication or fluids into the body using a needle and syringe. They can be administered intramuscularly, subcutaneously, or intravenously, depending on the specific needs of the patient.
- Oral Solids: Oral solids are pharmaceutical formulations in solid dosage forms, such as tablets, capsules, or powders, which are taken orally.
- Oral Liquids: Oral liquids refer to liquid pharmaceutical formulations that are meant to be taken by mouth, such as syrups, suspensions, or solutions.
Remus Pharmaceuticals Limited IPO Complete Details:
| IPO Date | 17 May 2023 to 19 May 2023 |
| Issue Type | Book Built Issue |
| Listing At | NSE SME |
| Face Value | 10 Rs. Per Share |
| Price | Rs. 1150 to 1229 |
| Lot Size | 100 |
| Issue Size | 388,000 shares (Rs.47.69 Cr) |
| Fresh Issue | 388,000 shares (Rs.47.69 Cr) |
| Listing Date | 29 May 2023 |
Remus Pharmaceuticals Limited IPO Timetable:
| Activity | Date* |
|---|---|
| Opening Date | 17 May 2023 |
| Closing Date | 19 May 2023 |
| Allotment | 24 May 2023 |
| Initiation of Refunds | 25 May 2023 |
| Credit of Shares to Demat Account | 26 May 2023 |
| Listing Date | 29 May 2023 |
Company Financial Details:
| Period Ended | Assets | Revenue | Profit After Tax | Borrowings | Reserves and Surplus |
|---|---|---|---|---|---|
| 31 March 2020 | 530.36 | 1,276.89 | 81.16 | 35.93 | 201.03 |
| 31 March 2021 | 1,104.96 | 1,922.45 | 102.58 | 27.89 | 303.61 |
| 31 March 2022 | 1,590.93 | 2,543.71 | 338.57 | 19.17 | 543.17 |
| 30 December 2022 | 3,352.96 | 3,361.20 | 643.90 | 947.45 | 1,603.57 |
AS OF NOW, the GMP OF Remus Pharmaceuticals Limited is Around 580 Rs.